Nadine Tung

30.2k total citations · 3 hit papers
190 papers, 11.3k citations indexed

About

Nadine Tung is a scholar working on Genetics, Oncology and Cancer Research. According to data from OpenAlex, Nadine Tung has authored 190 papers receiving a total of 11.3k indexed citations (citations by other indexed papers that have themselves been cited), including 116 papers in Genetics, 105 papers in Oncology and 59 papers in Cancer Research. Recurrent topics in Nadine Tung's work include BRCA gene mutations in cancer (113 papers), PARP inhibition in cancer therapy (44 papers) and Cancer Genomics and Diagnostics (40 papers). Nadine Tung is often cited by papers focused on BRCA gene mutations in cancer (113 papers), PARP inhibition in cancer therapy (44 papers) and Cancer Genomics and Diagnostics (40 papers). Nadine Tung collaborates with scholars based in United States, Canada and Poland. Nadine Tung's co-authors include Judy E. Garber, Susan M. Domchek, Mark E. Robson, Steven A. Narod, Binghe Xu, Anne Armstrong, Elżbieta Senkus, Pierfranco Conté, Norikazu Masuda and William D. Foulkes and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

Nadine Tung

183 papers receiving 11.0k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation

2017 2.2k citations Mark E. Robson, Seock‐Ah Im et al. profile →
OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer

2019 497 citations Mark E. Robson, Nadine Tung et al. profile →
Frequency of Germline Mutations in 25 Cancer Susceptibility Genes in a Sequential Series of Patients With Breast Cancer

2016 364 citations Nadine Tung, Nancy U. Lin et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Nadine Tung United States	53	5.9k	5.7k	3.9k	3.8k	1.7k	190	11.3k
Jeffrey N. Weitzel United States	49	5.1k 0.9×	4.7k 0.8×	4.1k 1.1×	3.0k 0.8×	1.1k 0.6×	222	10.3k
Ping Sun Canada	47	4.2k 0.7×	4.9k 0.9×	2.8k 0.7×	4.4k 1.2×	1.2k 0.7×	128	10.9k
Diana Eccles United Kingdom	49	4.6k 0.8×	2.9k 0.5×	3.6k 0.9×	2.6k 0.7×	550 0.3×	183	9.0k
Jennifer K. Litton United States	49	2.5k 0.4×	7.7k 1.4×	3.2k 0.8×	3.8k 1.0×	2.4k 1.4×	238	11.1k
Barbara L. Weber United States	43	5.3k 0.9×	2.8k 0.5×	5.2k 1.4×	2.2k 0.6×	458 0.3×	62	9.6k
Marc Tischkowitz United Kingdom	42	3.3k 0.6×	2.5k 0.4×	3.8k 1.0×	1.9k 0.5×	777 0.5×	157	7.3k
Judith Balmañà Spain	36	2.4k 0.4×	3.9k 0.7×	2.6k 0.7×	1.6k 0.4×	685 0.4×	179	6.5k
Gillian Mitchell Australia	29	2.5k 0.4×	3.5k 0.6×	2.6k 0.7×	1.4k 0.4×	917 0.5×	113	6.3k
Melody Cobleigh United States	39	1.6k 0.3×	10.5k 1.8×	4.3k 1.1×	3.8k 1.0×	2.8k 1.7×	131	14.7k
Charlie Gourley United Kingdom	39	1.9k 0.3×	5.5k 1.0×	3.9k 1.0×	1.4k 0.4×	796 0.5×	180	9.6k

Countries citing papers authored by Nadine Tung

Since Specialization

Citations

This map shows the geographic impact of Nadine Tung's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nadine Tung with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nadine Tung more than expected).

Fields of papers citing papers by Nadine Tung

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nadine Tung. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nadine Tung. The network helps show where Nadine Tung may publish in the future.

Co-authorship network of co-authors of Nadine Tung

This figure shows the co-authorship network connecting the top 25 collaborators of Nadine Tung. A scholar is included among the top collaborators of Nadine Tung based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nadine Tung. Nadine Tung is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hocaoğlu, Mevhibe, et al.. (2025). Implementing Pediatric Palliative Care in Vietnam: Initial Experiences and Lessons. Journal of Pain and Symptom Management. 71(3). 341–350.e3.

Tung, Nadine, et al.. (2024). Automated prediction of response to neoadjuvant chemotherapy from digitized H&E slides of pre-treatment core needle biopsies in germline BRCA carriers with HER2-negative breast cancer (TBCRC 031).. Journal of Clinical Oncology. 42(16_suppl). 605–605.

Ricker, Charité, Banu Arun, Sara Pirzadeh‐Miller, et al.. (2024). Selection of Germline Genetic Testing Panels in Patients With Cancer: ASCO Guideline Clinical Insights. JCO Oncology Practice. 20(10). 1308–1313. 3 indexed citations

Tung, Nadine, Mark E. Robson, Rita Nanda, et al.. (2024). TBCRC 048 (olaparib expanded) expansion cohorts: Phase 2 study of olaparib monotherapy in patients (pts) with metastatic breast cancer (MBC) with germline (g) mutations in PALB2 or somatic (s) mutations in BRCA1 or BRCA2.. Journal of Clinical Oncology. 42(16_suppl). 1021–1021. 8 indexed citations

Tolaney, Sara M., Nadine Tung, Antonio C. Wolff, et al.. (2024). HER2DX genomic test in early-stage HER2-positive breast cancer. ESMO Open. 9(12). 103987–103987. 8 indexed citations

Senkus, Elżbieta, Suzette Delaloge, Susan M. Domchek, et al.. (2023). Olaparib efficacy in patients with germline BRCA ‐mutated, HER2 ‐negative metastatic breast cancer: Subgroup analyses from the phase III OlympiAD trial. International Journal of Cancer. 153(4). 803–814. 16 indexed citations

Waks, Adrienne G., Guillermo Villacampa, Nadine Tung, et al.. (2023). 126MO HER2DX and pathological complete response in HER2-positive breast cancer: A combined analysis of 4 neoadjuvant studies. ESMO Open. 8(1). 101465–101465. 1 indexed citations

Schonberg, Mara A., Adlin Pinheiro, Roger B. Davis, et al.. (2022). Variation in Breast Cancer Risk Model Estimates Among Women in Their 40s Seen in Primary Care. Journal of Women s Health. 31(4). 495–502. 4 indexed citations

Vaz-Luís, Inês, Tianyu Li, Nabihah Tayob, et al.. (2021). A phase II study of efficacy, toxicity, and the potential impact of genomic alterations on response to eribulin mesylate in combination with trastuzumab and pertuzumab in women with human epidermal growth factor receptor 2 (HER2)+ metastatic breast cancer. Breast Cancer Research and Treatment. 189(2). 411–423. 4 indexed citations

10.

Tung, Nadine, et al.. (2021). Adjuvant PARP Inhibitors in Patients With High-Risk Early-Stage HER2-Negative Breast Cancer and Germline BRCA Mutations: ASCO Hereditary Breast Cancer Guideline Rapid Recommendation Update. Journal of Clinical Oncology. 39(26). 2959–2961. 36 indexed citations

11.

Schwartz, Alison, Danielle Castillo, Nadine Tung, et al.. (2021). Evaluation of TP53 Variants Detected on Peripheral Blood or Saliva Testing: Discerning Germline From Somatic TP53 Variants. JCO Precision Oncology. 5(5). 1677–1686. 12 indexed citations

12.

Song, Yun, William T. Barry, Davinia Seah, et al.. (2019). Patterns of recurrence and metastasis in BRCA1/BRCA2‐associated breast cancers. Cancer. 126(2). 271–280. 78 indexed citations

13.

Tung, Nadine & Judy E. Garber. (2018). BRCA1/2 testing: therapeutic implications for breast cancer management. British Journal of Cancer. 119(2). 141–152. 133 indexed citations

14.

Birkbak, Nicolai J., Zhigang C. Wang, Ji-Young Kim, et al.. (2012). Telomeric Allelic Imbalance Indicates Defective DNA Repair and Sensitivity to DNA-Damaging Agents. Cancer Discovery. 2(4). 366–375. 412 indexed citations

15.

Martins, Filipe Correia, Subhajyoti De, Vanessa Almendro, et al.. (2012). Evolutionary Pathways in BRCA1-Associated Breast Tumors. Cancer Discovery. 2(6). 503–511. 95 indexed citations

16.

Yang, Shi, et al.. (2012). c‐myc in Kaposi’s sarcoma: analyses by fluorescent in situ hybridization and immunohistochemistry. Journal of the European Academy of Dermatology and Venereology. 28(1). 120–124. 4 indexed citations

17.

Li, Huchun, Masayuki Sekine, Nadine Tung, & Hava Avraham. (2010). Wild-Type BRCA1, but not Mutated BRCA1, Regulates the Expression of the Nuclear Form of β-Catenin. Molecular Cancer Research. 8(3). 407–420. 14 indexed citations

18.

Vicus, Danielle, Barry P. Rosen, Jan Lubiński, et al.. (2009). Tamoxifen and the risk of ovarian cancer in BRCA1 mutation carriers. Gynecologic Oncology. 115(1). 135–137. 11 indexed citations

19.

Metcalfe, Kelly, Henry T. Lynch, P Ghadirian, et al.. (2005). The Risk of Ovarian Cancer After Breast Cancer in BRCA1 and BRCA2 Carriers. Obstetrical & Gynecological Survey. 60(4). 235–236. 9 indexed citations

20.

Foulkes, William D., Kelly Metcalfe, Wedad Hanna, et al.. (2003). Disruption of the expected positive correlation between breast tumor size and lymph node status in BRCA1‐related breast carcinoma. Cancer. 98(8). 1569–1577. 84 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact